At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-4482 in Healthy Participants Inoculated With Experimental Respiratory Syncytial Virus
In Brief
A Phase 2 clinical trial evaluating Molnupiravir, Placebo, and 1 other intervention for Respiratory Syncytial Virus. Completed, enrolled 116 participants across 1 site.
Detailed Summary
This is a study of molnupiravir (MK-4482) in healthy participants who have been inoculated with an experimental Respiratory Syncytial Virus (RSV) \[RSV-A Memphis 37b\]. It is hypothesized that treatment with the drug MK-4482 (molnupiravir) will reduce the peak viral load (PVL) in the participant compared to placebo when given either before or after RSV-A Memphis 37b inoculation.
Study Details
Timeline
Interventions
Four molnupiravir 200 mg capsules (800 mg total dose) taken twice daily by mouth.
Placebo capsule matched to molnupiravir taken twice daily by mouth.
RSV A Memphis 37b viral challenge given once by intranasal administration at a dosage of \~4 Log10 plaque forming units (PFUs).